Literature DB >> 27856964

Neonatal Satellite Cells Form Small Myotubes In Vitro.

P L Carvajal Monroy1, S Grefte2, A M Kuijpers-Jagtman1, J W Von den Hoff1, F A D T G Wagener1.   

Abstract

Although palatal muscle reconstruction in patients with cleft palate takes place during early childhood, normal speech development is often not achieved. We hypothesized that the intrinsic properties of head satellite cells (SCs) and the young age of these patients contribute to the poor muscle regeneration after surgery. First, we studied the fiber type distribution and the expression of SC markers in ex vivo muscle tissue from head (branchiomeric) and limb (somite-derived) muscles from neonatal (2-wk-old) and young (9-wk-old) rats. Next, we cultured SCs isolated from these muscles for 5, 7, and 9 d, and investigated the in vitro expression of SC markers, as well as changes in proliferation, early differentiation, and fusion index (myotube formation) in these cells. In our ex vivo samples, we found that virtually all myofibers in both the masseter (Mass) and the levator veli palatini (LVP) muscles contained fast myosin heavy chain (MyHC), and a small percentage of digastric (Dig) and extensor digitorum longus myofibers also contained slow MyHC. This was independent of age. More SCs were found in muscles from neonatal rats as compared with young rats [17.6 (3.8%) v. 2.3 (1.6%); P < 0.0001]. In vitro, young branchiomeric head muscle (BrHM) SCs proliferated longer and differentiated later than limb muscle SCs. No differences were found between SC cultures from the different BrHMs. SC cultures from neonatal muscles showed a much higher proliferation index than those from young animals at 5 d (0.8 v. 0.2; P < 0.001). In contrast, the fusion index in neonate SCs was about twice as low as that in SCs from young muscles at 9 d [27.6 (1.4) v. 62.8 (10.2), P < 0.0001]. In conclusion, SCs from BrHM differ from limb muscles especially in their delayed differentiation. SCs from neonatal muscles form myotubes less efficiently than those from young muscles. These age-dependent differences in stem cell properties urge careful consideration for future clinical applications in patients with cleft palate.

Entities:  

Keywords:  cleft palate; cranio-maxillofacial surgery; craniofacial anomalies; craniofacial biology/genetics; muscle biology; stem cells

Mesh:

Substances:

Year:  2016        PMID: 27856964     DOI: 10.1177/0022034516679136

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  5 in total

1.  The Myotube Analyzer: how to assess myogenic features in muscle stem cells.

Authors:  Simon Noë; Marlies Corvelyn; Sarah Willems; Domiziana Costamagna; Jean-Marie Aerts; Anja Van Campenhout; Kaat Desloovere
Journal:  Skelet Muscle       Date:  2022-06-10       Impact factor: 5.063

Review 2.  Tissue engineering strategies combining molecular targets against inflammation and fibrosis, and umbilical cord blood stem cells to improve hampered muscle and skin regeneration following cleft repair.

Authors:  Michaël Schreurs; C Maarten Suttorp; Henricus A M Mutsaers; Anne Marie Kuijpers-Jagtman; Johannes W Von den Hoff; Edwin M Ongkosuwito; Paola L Carvajal Monroy; Frank A D T G Wagener
Journal:  Med Res Rev       Date:  2019-05-18       Impact factor: 12.944

3.  Effect of niche components on masseter satellite cell differentiation on fibrin coatings.

Authors:  Olivier Willem Lijten; Doris Haydee Rosero Salazar; Merijn van Erp; Ewald Bronkhorst; Johannes W Von den Hoff
Journal:  Eur J Oral Sci       Date:  2022-01-12       Impact factor: 2.160

4.  Wnt7a induces satellite cell expansion, myofiber hyperplasia and hypertrophy in rat craniofacial muscle.

Authors:  Xu Cheng; Hanyao Huang; Xiangyou Luo; Bing Shi; Jingtao Li
Journal:  Sci Rep       Date:  2018-07-13       Impact factor: 4.379

Review 5.  Orofacial Muscles: Embryonic Development and Regeneration after Injury.

Authors:  D H Rosero Salazar; P L Carvajal Monroy; F A D T G Wagener; J W Von den Hoff
Journal:  J Dent Res       Date:  2019-11-01       Impact factor: 6.116

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.